

Rec'd 11/5/07

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Sheet 1 of 1

ATTORNEY DOCKET NO.: PAT-0040-US-NP2

INFORMATION DISCLOSURE CITATION

APPLICATION NO.: 10/603,406

(Use several sheets if necessary)

APPLICANT: BOREA et al.

FILING DATE: June 24, 2003

Group: 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/S.G./	A01	U.S. 6,921,825	07/26/2005	Baraldi et al.	544	251	04/26/2002
	A02						
	A03						
	A04						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01						<input type="checkbox"/>	<input type="checkbox"/>
	B02						<input type="checkbox"/>	<input type="checkbox"/>
	B03						<input type="checkbox"/>	<input type="checkbox"/>
	B04						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/S.G./	C01	Baraldi et al., "Pyrozolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A ₃ Adenosine Receptor Antagonists: Influence of the Chain at the N ⁸ Pyrazole Nitrogen", <i>Journal of Medicinal Chemistry</i> 2000, 43, 4768-4780.
/S.G./	C02	Baraldi et al., "Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrozolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A ₃ Adenosine Receptor Antagonists", <i>Journal of Medicinal Chemistry</i> 2002, 45, 770-780.
	C03	
	C04	
	C05	
	C09	
	C10	
	C11	

EXAMINER

/Shirley Gembeh/

DATE CONSIDERED

11/20/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.